Suresh Chandran

Prof. Dr. Suresh Chandran

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Translational Pediatrics
Verified
Journal Article
Open access
PDF file
EHEman Awadh Abduladheem Hashim
Eman Awadh Abduladheem Hashim
BQBin Huey Quek
Bin Huey Quek
SCSuresh Chandran
Suresh Chandran
Poland’s syndrome (PS) is a rare musculoskeletal congenital anomaly with a wide spectrum of presentations. It is typically characterized by hypoplasia or aplasia of pectoral muscles, mammary hypoplasia and variably associated ipsilateral limb anomalies. Limb defects can vary in severity, ranging from syndactyly to phocomelia. Most cases are sporadic but familial cases with intrafamilial variability have been reported. Several theories have been proposed regarding the genesis of PS. Vascular disruption theory, “the subclavian artery supply disruption sequence” (SASDS) remains the most accepted pathogenic mechanism. Clinical presentations can vary in severity from syndactyly to phocomelia in the limbs and in the thorax, rib defects to severe chest wall anomalies with impaired lung function. Most patients have subtle presentation at birth and milder forms in childhood. Functional limitations due to PS are usually minimal. Surgical treatment aims to improve pulmonary functions arising from severe thoracic deformities but is more often done to enhance the cosmesis. The use of adipose-derived mesenchymal stem cells and fat transfer have shown promising results in recent times for correction of chest defects and breast augmentation. Gaining deeper insights into the etiopathogenesis and clinical presentation of PS will improve the clinical recognition and management of this rare condition. In this review article, we aim to outline the details of this syndrome including its etiopathogenesis, evolution, spectrum of clinical manifestations, other systemic associations, diagnostic modalities, and recent advances in treatment.

1 August 2019 in Journal of Medical Microbiology
Verified
Journal Article
Open access
JCJ. C. Chan
J. C. Chan
CCChiayin Chong
Chiayin Chong
KTKoh Cheng Thoon
Koh Cheng Thoon
NTN. W. S. Tee
N. W. S. Tee
MMMatthias Maiwald
Matthias Maiwald
NTNatalie Woon Hui Tan
Natalie Woon Hui Tan
Objectives. Elizabethkingia meningoseptica is a multi-drug-resistant organism that is associated with high mortality and morbidity in newborn and immunocompromised patients. This study aimed to identify the best antimicrobial therapy for treating this infection. Methods. A retrospective descriptive study was conducted from 2010 to 2017 in a tertiary paediatric hospital in Singapore. Paediatric patients aged 0 to 18 years old with a positive culture for E. meningoseptica from any sterile site were identified from the hospital laboratory database. The data collected included clinical characteristics, antimicrobial susceptibility and treatment, and clinical outcomes. Results. Thirteen cases were identified in this study. Combination therapy with piperacillin/tazobactam and trimethoprim/sulfamethoxazole or a fluoroquinolone resulted in a cure rate of 81.8 %. The mortality rate was 15.4 % and neurological morbidity in patients with bacteraemia and meningitis remained high (75 %). Conclusions. Treatment with combination therapy of piperacillin/tazobactam and trimethoprim/sulfamethoxazole or a fluroquinolone was effective in this study, with low mortality rates being observed.

9 December 2020 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
SCSuresh Chandran
Suresh Chandran
AAAmudha Jayanthi Anand
Amudha Jayanthi Anand
VRVictor Samuel Rajadurai
Victor Samuel Rajadurai
Seyed Ehsan SaffariSeyed Ehsan Saffari
Seyed Ehsan Saffari
PKPoh Choo Khoo
Poh Choo Khoo
MCMei Chien Chua
Mei Chien Chua

2 September 2020 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
LSLoo Sooklin
Loo Sooklin
AAAmudha Jayanthi Anand
Amudha Jayanthi Anand
VRVictor Samuel Rajadurai
Victor Samuel Rajadurai
SCSuresh Chandran
Suresh Chandran
Congenital chylous ascites is a rare cause of ascites in newborn infants. Its aetiology varies from localised leaky lymphatic duct to genetic syndromes. Most of these cases have transient ascites resolving over time with conservative management but some may progress needing medical as well as surgical treatment. We describe a case of antenatally detected large fetal ascites necessitating abdominal paracentesis and amnioreduction. Marked respiratory distress at birth required urgent abdominal paracentesis to relieve symptoms. The infant initially showed a good response to medium chain triglyceride (MCT) based formula milk feeds. Feeds were discontinued for 3 weeks due to sepsis with ileus. On recovery, recommencement of feeds resulted in reaccumulation of ascites. As the response to MCT-based formula was inadequate, octreotide therapy was initiated. Ascites showed remarkable resolution over the next 2 weeks and was discharged home. Follow-up at 5 years of age revealed normal growth and neurodevelopment.

20 September 2021 in Archives of Disease in Childhood - Fetal and Neonatal Edition
Verified
Journal Article
Closed access
PDF file
SCSuresh Chandran
Suresh Chandran
PRPravin R R
Pravin R R
MCMei Chien Chua
Mei Chien Chua
Seyed Ehsan SaffariSeyed Ehsan Saffari
Seyed Ehsan Saffari
VRVictor Samuel Rajadurai
Victor Samuel Rajadurai
FYFabian Yap
Fabian Yap
Objectives Diazoxide (DZX) is the drug of choice for treating hyperinsulinaemic hypoglycaemia (HH), and it has potentially serious adverse effects. We studied the safety and efficacy of low-dose DZX in small-for-gestational-age (SGA) infants with HH. Design An observational cohort study from 1 September 2014 to 31 September 2020. Setting A tertiary Women’s and Children’s Hospital in Singapore. Patients All SGA infants with HH. Intervention Diazoxide, at 3–5 mg/kg/day. Main outcome measures Short-term outcomes; adverse drug events and fasting studies to determine ‘safe to go home’ and ‘resolution’ of HH. Results Among 71 836 live births, 11 493 (16%) were SGA. Fifty-six (0.5%) SGA infants with HH were identified, of which 27 (47%) with a mean gestational age of 36.4±2 weeks and birth weight of 1942±356 g required DZX treatment. Diazoxide was initiated at 3 mg/kg/day at a median age of 10 days. The mean effective dose was 4.6±2.2 mg/kg/day, with 24/27 (89%) receiving 3–5 mg/kg/day. Generalised hypertrichosis occurred in 2 (7.4%) and fluid retention in 1 (3.7%) infant. A fasting study was performed before home while on DZX in 26/27 (96%) cases. Diazoxide was discontinued at a median age of 63 days (9–198 days), and resolution of HH was confirmed in 26/27 (96%) infants on passing a fasting study. Conclusion Our study demonstrates that low-dose DZX effectively treats SGA infants with HH as measured by fasting studies. Although the safety profile was excellent, minimal adverse events were still observed with DZX, even at low doses.

11 February 2020 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
SCSuresh Chandran
Suresh Chandran
AAArpan Agarwal
Arpan Agarwal
GLGenevieve Villablanca Llanora
Genevieve Villablanca Llanora
MCMei Chien Chua
Mei Chien Chua
Octreotide is a somatostatin analogue used for treating congenital chylothorax and congenital hyperinsulinism in infants. By increasing splanchnic arteriolar resistance and decreasing gastrointestinal blood flow, octreotide indirectly reduces lymphatic flow in chylous effusions. Splanchnic ischaemia following octreotide predisposes infants to necrotising enterocolitis (NEC). Although NEC occurrence in infants treated with octreotide for hyperinsulinaemic hypoglycaemia has been reported widely, its incidence in infants with chylothroax is low. We describe a case of congenital chylothorax in a preterm infant who had poor response to thoracentesis. Although octreotide initiation lead to resolution of chylothorax, he developed NEC. Cessation of octreotide and medical management resulted in rapid resolution of NEC. Since octreotide is generally used as the first-line treatment for chylous effusion, the risk of NEC should be considered, especially when the dosage is increased. Infants on octreotide should be closely observed for early signs and symptoms of NEC to avert surgical emergency.